At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 343 enrolled
Drug / intervention
Ticagrelor +1 moredrug
Likely dose
Ticagrelor 180 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
In Brief
A Phase 4 clinical trial evaluating Ticagrelor and Clopidogrel for Acute Coronary Syndrome. Completed, enrolled 343 participants across 16 sites.
Detailed Summary
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJul 2012
Primary CompletionJun 2014
TodayJul 2026
First PostedMay 22, 2012
Enrollment StartJul 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.1 years ago
Interventions
Ticagrelordrug
180 mg loading dose
Clopidogreldrug
600 mg loading dose